Электронная медицинская библиотека Румедо.

Зарубежные материалы

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Дата публикации 22.10.2020
Автор: Benjamin M. Scirica, M.D., M.P.H., Deepak L. Bhatt, M.D., M.P.H., Eugene Braunwald, M.D., P. Gabriel Steg, M.D., Jaime Davidson, M.D., Boaz Hirshberg, M.D., Peter Ohman, M.D., Robert Frederich, M.D., Ph.D., Stephen D. Wiviott, M.D., Elaine B. Hoffman, Ph.D., Matthew A. Cavender, M.D., M.P.H., Jacob A. Udell, M.D., M.P.H., Nihar R. Desai, M.D., M.P.H., Ofri Mosenzon, M.D., Darren K. McGuire, M.D., Kausik K. Ray, M.D., Lawrence A. Leiter, M.D., and Itamar Raz, M.D., for the SAVOR-TIMI 53 Steering Committee and Investigators

The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.

Подробнее

869

Зарубежные материалы

Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus Death

Дата публикации 22.10.2020
Автор: Lorien S. Dalrymple, MD, MPH1, Ronit Katz, DPhil 2, Bryan Kestenbaum, MD, MS 3, Michael G. Shlipak, MD, MPH4,5, Mark J. Sarnak, MD, MS 6, Catherine Stehman-Breen, MD, MS 7, Stephen Seliger, MD, MS 8, David Siscovick, MD, MPH3,9, Anne B. Newman, MD, MPH10,11, and Linda Fried, MD, MPH10,11,12

In the United States, approximately one in three adults aged 65 years and older has chronic kidney disease (CKD), defined as an eGFR ...

Подробнее

775

Зарубежные материалы

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

Дата публикации 22.10.2020
Автор: Steven E. Kahn, M.B., Ch.B., Steven M. Haffner, M.D., Mark A. Heise, Ph.D., William H. Herman, M.D., M.P.H., Rury R. Holman, F.R.C.P., Nigel P. Jones, M.A., Barbara G. Kravitz, M.S., John M. Lachin, Sc.D., M. Colleen O’Neill, B.Sc., Bernard Zinman, M.D., F.R.C.P.C., and Giancarlo Viberti, M.D., F.R.C.P., for the ADOPT Study Group *

The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known.

Подробнее

773

Зарубежные материалы

Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial

Дата публикации 22.10.2020
Автор: Richard I. G. Holt, Rebecca Gossage-Worrall, Daniel Hind, Michael J. Bradburn, Paul McCrone, Tiyi Morris, Charlotte Edwardson, Katharine Barnard, Marian E. Carey, Melanie J. Davies, Chris M. Dickens, Yvonne Doherty, Angela Etherington, Paul French, Fiona Gaughran, Kathryn E. Greenwood, Sridevi Kalidindi, Kamlesh Khunti, Richard Laugharne, John Pendlebury, Shanaya Rathod, David Saxon, David Shiers, Najma Siddiqi, Elizabeth A. Swaby, Glenn Waller and Stephen Wright on behalf of the STEPWISE Research Group*

People with schizophrenia die 10–20 years earlier than the general population, with approximately 75% of deaths resulting from physical illness.1 The twofold increased prevalence of overweight and obesity contributes to this excess mortality.2 Some, but not all, studies suggest that dietary

Подробнее

658

Зарубежные материалы

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Дата публикации 22.10.2020
Автор: Bernard Zinman, M.D., Christoph Wanner, M.D., John M. Lachin, Sc.D., David Fitchett, M.D., Erich Bluhmki, Ph.D., Stefan Hantel, Ph.D., Michaela Mattheus, Dipl. Biomath., Theresa Devins, Dr.P.H., Odd Erik Johansen, M.D., Ph.D., Hans J. Woerle, M.D., Uli C. Broedl, M.D., and Silvio E. Inzucchi, M.D., for the EMPA-REG OUTCOME Investigators

The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.

Подробнее

869

Зарубежные материалы

Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns — NHANES 2007–2012

Дата публикации 22.10.2020
Автор: Bingcao Wu, Kelly Bell, Amy Stanford, David M Kern, Ozgur Tunceli, Suma Vupputuri, Iftekhar Kalsekar, Vincent Willey

To describe the estimated prevalence and temporal trends of chronic kidney disease (CKD) treatment patterns, and the association between CKD and potential factors for type 2 diabetes mellitus (T2DM) in different demographic subgroups.

Подробнее

726

Зарубежные материалы

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (The new england journal of medicine)

Дата публикации 22.10.2020
Автор: Steven P. Marso, M.D., Gilbert H. Daniels, M.D., Kirstine Brown-Frandsen, M.D., Peter Kristensen, M.D., E.M.B.A., Johannes F.E. Mann, M.D., Michael A. Nauck, M.D., Steven E. Nissen, M.D., Stuart Pocock, Ph.D., Neil R. Poulter, F.Med.Sci., Lasse S. Ravn, M.D., Ph.D., William M. Steinberg, M.D., Mette Stockner, M.D., Bernard Zinman, M.D., Richard M. Bergenstal, M.D., and John B. Buse, M.D., Ph.D., for the LEADER Steering Committee on behalf of the LEADER Trial Investigators

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.

Подробнее

680

Зарубежные материалы

Prevalence of Low Glomerular Filtration Rate in Nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III)

Дата публикации 22.10.2020
Автор: Department of Medicine, McMaster University, Hamilton, Ontario; Department of Medicine, University of Western Ontario, London, Ontario; Health Research Methodology Graduate Program, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario; and Department of Medicine, Dalhousie University, Halifax, Nova Scotia

End-stage renal disease is an important and costly health problem. Strategies for its prevention are urgently needed. Knowledge of the population-based prevalence of renal insufficiency in nondiabetic adults would inform such strategies.

Подробнее

688

Статьи

Инициация терапии сахарного диабета 2 типа: новые возможности

Дата публикации 22.10.2020
Автор: А.М. Мкртумян, д.м.н., проф.

В настоящее время сахарный диабет (СД) 2 типа является глобальной проблемой здравоохранения – распространенность патологии достигла масштабов эпидемии как в развитых, так и развивающихся странах

Подробнее

764

Зарубежные материалы

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

Дата публикации 22.10.2020
Автор: William B. White, M.D., Christopher P. Cannon, M.D., Simon R. Heller, M.D., Steven E. Nissen, M.D., Richard M. Bergenstal, M.D., George L. Bakris, M.D., Alfonso T. Perez, M.D., Penny R. Fleck, M.B.A., Cyrus R. Mehta, Ph.D., Stuart Kupfer, M.D., Craig Wilson, Ph.D., William C. Cushman, M.D., and Faiez Zannad, M.D., Ph.D., for the EXAMINE Investigators

To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 ...

Подробнее

1005

Зарубежные материалы

2018 ESC/ESH Guidelines for the management of arterial hypertension

Дата публикации 22.10.2020
Автор: Bryan Williams* (ESC Chairperson) (UK), Giuseppe Mancia* (ESH Chairperson) (Italy), Wilko Spiering (The Netherlands), Enrico Agabiti Rosei (Italy), Michel Azizi (France), Michel Burnier (Switzerland), Denis L. Clement (Belgium), Antonio Coca (Spain), Giovanni de Simone (Italy), Anna Dominiczak (UK), Thomas Kahan (Sweden), Felix Mahfoud (Germany), Josep Redon (Spain), Luis Ruilope (Spain), Alberto Zanchetti† (Italy), Mary Kerins (Ireland), Sverre E. Kjeldsen (Norway), Reinhold Kreutz (Germany), Stephane Laurent (France), Gregory Y. H. Lip (UK), Richard McManus (UK), Krzysztof Narkiewicz (Poland), Frank Ruschitzka (Switzerland), Roland E. Schmieder (Germany), Evgeny Shlyakhto (Russia), Costas Tsioufis (Greece), Victor Aboyans (France), and Ileana Desormais (France)

The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)

Подробнее

825

Зарубежные материалы

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus

Дата публикации 22.10.2020
Автор: John B. Buse, MD, PhD, Co-chair; Henry N. Ginsberg, MD, FAHA, Co-chair; George L. Bakris, MD, FAHA; Nathaniel G. Clark, MD, MS, RD; Fernando Costa, MD, FAHA; Robert Eckel, MD, FAHA; Vivian Fonseca, MD; Hertzel C. Gerstein, MD, MSc, FRCPC; Scott Grundy, MD, FAHA; Richard W. Nesto, MD, FAHA; Michael P. Pignone, MD, MPH; Jorge Plutzky, MD; Daniel Porte, MD; Rita Redberg, MD, FAHA; Kimberly F. Stitzel, MS, RD; Neil J. Stone, MD, FAHA

Abstract—The American Heart Association (AHA) and the American Diabetes Association (ADA) have each published guidelines for cardiovascular disease prevention: The ADA has issued separate recommendations for each of the cardiovascular risk factors in patients with diabetes, and the AHA has shaped primary and secondary guidelines that extend to patients with diabetes. This statement will attempt to ...

Подробнее

819

Зарубежные материалы

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Дата публикации 22.10.2020
Автор: Jennifer B. Green, M.D., M. Angelyn Bethel, M.D., Paul W. Armstrong, M.D., John B. Buse, M.D., Ph.D., Samuel S. Engel, M.D., Jyotsna Garg, M.S., Robert Josse, M.B., B.S., Keith D. Kaufman, M.D., Joerg Koglin, M.D., Scott Korn, M.D., John M. Lachin, Sc.D., Darren K. McGuire, M.D., M.H.Sc., Michael J. Pencina, Ph.D., Eberhard Standl, M.D., Ph.D., Peter P. Stein, M.D., Shailaja Suryawanshi, Ph.D., Frans Van de Werf, M.D., Ph.D., Eric D. Peterson, M.D., M.P.H., and Rury R. Holman, M.B., Ch.B., for the TECOS Study Group*

Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease.

Подробнее

624

Статьи

Особенности почечной патологии у больных сахарным диабетом 2 типа

Дата публикации 22.10.2020
Автор: М.Ш. Шамхалова, Н.П. Трубицына, Н.В. Зайцева, М.В. Шестакова

Сахарный диабет [СД] 2 типа относится к числу наиболее распространенных заболеваний.

Подробнее

790

Зарубежные материалы

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and theEuropeanAssociation for the Study of Diabetes (EASD)

Дата публикации 22.10.2020
Автор: Melanie J. Davies,1,2 David A. D’Alessio,3 Judith Fradkin,4 Walter N. Kernan,5 Chantal Mathieu,6 Geltrude Mingrone,7,8 Peter Rossing,9,10 Apostolos Tsapas,11 Deborah J. Wexler,12,13 and John B. Buse14

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education ...

Подробнее

765

БИБЛИОТЕКА